Navigation Links
Statement from CHPA on Today's FDA Advisory Committee Meeting on Dextromethorphan
Date:9/14/2010

WASHINGTON, Sept. 14 /PRNewswire-USNewswire/ --  The Consumer Healthcare Products Association issued the following statement on the Drug Safety and Risk Management Advisory Committee's recommendation not to schedule over-the-counter (OTC) medicines containing dextromethorphan:

"Today's FDA advisory committee decision not to recommend scheduling OTC cough medicines containing dextromethorphan as a controlled substance reflects a sound balancing of the benefits of over-the-counter medicines containing dextromethorphan.

"Today, 40 million American households turn to dextromethorphan-containing OTC medicines each year to relieve their cough symptoms. More common than heartburn and severe headaches, cough burdens the sufferer, families, and society (as a very rapid way to spread virus).  Because of cough's widespread prevalence and effects, it's vital for people to have OTC access to safe and effective self-treatment. Dextromethorphan is in nearly 90 percent of OTC cough suppressants sold today. We agree that dextromethorphan should not be scheduled as a controlled substance.

"We do, however, recognize the need for continued education to keep any abuse levels low. We also have long called for federal legislation that would limit purchases of bulk quantities of dextromethorphan to manufacturers who are registered with FDA. We believe that a statutory ban on sales of dextromethorphan medicines to those under 18 would limit abuse. We also believe legislation must be matched with targeted research-based education, which has been shown to be effective in reducing substance abuse.

"Research over the past 35 years clearly shows that targeted educational interventions focusing on increased parental awareness and increased perceptions of the risks and social disapproval are the most effective abuse-reduction strategies. Since 2003, we have had educational programs focusing on the dangers of misuse of over-the-counter medicines, including those containing dextromethorphan. We will continue to expand upon these programs through our comprehensive Abuse Mitigation Plan that targets the key risk factors leading to abuse, along with limiting the various points where teens are accessing these medicines.

"It is our hope that FDA will follow the advisory committee's guidance and weigh the important public benefit of continued over-the-counter access to these medicines in making its final recommendation."

CHPA is the 129-year-old-trade association representing U.S. manufacturers and distributors of over-the-counter medicines and nutritional supplements.

www.chpa-info.org

www.chpa-info.org/pressroom/2010PK_DXM.aspx


'/>"/>
SOURCE Consumer Healthcare Products Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Media Statement: Robert Moussa, President and CEO, Dilon Diagnostics
2. Statement from Eli Lilly and Company Regarding Approval Recommendation from FDA Advisory Committee for Expanding the Pain Indications for Cymbalta® to a Broader Pain Population
3. Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering
4. NCPA Statement on CVS Caremark-Aetna Agreement
5. GlaxoSmithKline Statement in Response to FDA Advisory Committees Vote on Safety of Avandia® (rosiglitazone)
6. Dendreon Statement on CMS National Coverage Analysis
7. NORD Calls for Statement of Policy on Orphan Drug Development
8. Teva Admits to Making False Statements in US Gianvi™ Label and Agrees to Corrective Measures
9. Alexza Pharmaceuticals Files Shelf Registration Statement
10. FDA Issues Statement on Baxters Recall of Colleague Infusion Pumps
11. Pew Statement on the Physician Payments Sunshine Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 ... ... the patient payment industry today announced its strategic partnership with Connance, a ... workflows. , The two companies’ proven, proprietary technology combine to provide health ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):